# Pacira BioSciences Inc. (PCRX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Pharmaceuticals. Price $26.35, market value $1.1 billion.

## Valuation
- **P/E (trailing): 75.3×** (5-yr avg 94.7×, 3-yr avg 99.8×). Pacira BioSciences Inc. trades at 75.3× trailing earnings, well below its own five-year average of 94.7×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 7.6×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.07**. A PEG of 0.07 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 1.4×**. Each dollar of revenue is priced at 1.4×.
- **Price / book: 1.6×**. The shares trade at 1.6× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 12.0×**. Enterprise value is 12.0× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 17.1%** (5-yr avg 9.9%). Free cash flow equals 17.1% of the market value, above its five-year average of 9.9%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 1.3%**. The inverse of the P/E: 1.3% of the price is earned each year.

## Profitability
- **Operating margin: 2.7%**. 2.7% of revenue is left after running the business, which leaves little cushion in a downturn.
- **Net margin: 1.0%**. 1.0% of each dollar of sales reaches the bottom line.
- **Return on equity: 1.0%**. 1.0% on shareholders' equity is weak; the business earns little on the capital its owners have in it.
- **Return on invested capital: 1.7%**. Return on all capital, debt included, is 1.7%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: 1.2%**. Each dollar of assets produces 1.2% of profit.

## Growth
- **Revenue growth (1 yr): 3.6%** (3-yr 2.9%/yr, 5-yr 11.1%/yr). Revenue grew 3.6% over the last year, against 11.1% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 107.4%** (3-yr -22.2%/yr, 5-yr -45.5%/yr). Earnings per share rose 107.4%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 5.9%/yr**. Free cash flow has compounded at 5.9% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.54**. Debt is 0.54 times equity, moderate leverage.
- **Net debt / EBITDA: 2.0×**. It would take 2.0 years of operating earnings to repay net borrowings, within the comfortable range.
- **Altman Z-score: 2.49**. A Z-score of 2.49 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Pacira BioSciences Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (7 analysts). 7 analysts cover Pacira BioSciences Inc.; the consensus is buy, with an average price target of $30.00 (+14% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -1.4%** (YTD 1.8%, 3-mo 15.8%). The shares are down 1.4% over twelve months including dividends.
- **From 52-week high: -4.7%** (40.2% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 59**. An RSI of 59 is neutral.
- **Beta (1 yr): 0.35** (volatility 37%). Beta of 0.35 against the S&P 500: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=PCRX · Page: https://foliofundamentals.com/stocks/pcrx

Not investment advice.